D. Maraninchi, Pharmaciens et Institut national du cancer : Partenaires pour la mise en oeuvre du Plan Cancer. 19e Journée de l'Ordre, Paris le 9 novembre 2006, Bulletin de l'ordre des pharmaciens, vol.393, pp.421-429, 2006.

/. Circulaire-n°dhos and . 1c, relative à la mise en oeuvre du contrat de bon usage des médicaments et produits et prestations mentionné à l'article L, pp.162-184, 2006.

J. Trivier, Présentation générale des OMEDITs, Réunion APHNEP, 2007.

B. Begaud, J. Evreux, J. Jouglard, and G. Lagier, Imputabilité des effets inattendus ou toxiques des médicaments, Thérapie, vol.40, pp.111-119, 1985.

T. Kelesidis, G. Daikos, D. Boumpas, and S. Tsiodras, Does rituximab increase the incidence of infectious complications? A narrative review, International Journal of Infectious Diseases, vol.15, issue.1, pp.2-16, 2011.
DOI : 10.1016/j.ijid.2010.03.025

H. Gürcan, D. Keskin, J. H. Stern, M. Nitzberg, A. Shekhani et al., A review of the current use of rituximab in autoimmune diseases, International Immunopharmacology, vol.9, issue.1, pp.10-25, 2009.
DOI : 10.1016/j.intimp.2008.10.004

M. Ramos-casals, P. Brito-zero´n, S. Mun?oz, . Soto, and . Group, A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases, Medicine, vol.87, issue.6, pp.345-364, 2008.
DOI : 10.1097/MD.0b013e318190f170

J. Peterson and L. Chan, Effectiveness and side effects of anti-CD20 therapy for autoantibodymediated blistering skin diseases: A comprehensive survey of 71consecutive patients from the Initial use to, Therapeutics and Clinical Risk Management, vol.5, pp.1-7, 2007.

E. Schmidt, D. Goebeler, and . Zillikensa, Rituximab in Severe Pemphigus, Annals of the New York Academy of Sciences, vol.30, issue.Suppl 1, pp.683-691, 2009.
DOI : 10.1111/j.1749-6632.2009.04744.x

N. Cooper and D. M. Arnold, The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases, British Journal of Haematology, vol.60, issue.Suppl 2, pp.3-13, 2010.
DOI : 10.1111/j.1365-2141.2010.08076.x

E. Schmidt and M. Goebeler, CD20-directed therapy in autoimmune diseases involving the skin: role of rituximab, Expert Review of Dermatology, vol.3, issue.3, pp.259-278, 2008.
DOI : 10.1586/17469872.3.3.259

R. Looney, R. Srinivasan, and L. H. Calabrese, The effects of rituximab on immunocompetency in patients with autoimmune disease, Arthritis & Rheumatism, vol.3, issue.1, pp.5-14, 2008.
DOI : 10.1002/art.23171

L. Sailler, C. Attane, . Michenot, . Jm-canonge, E. Rostaing et al., Rituximab off-label use for immune diseases: assessing adverse events in a single-centre drug-utilization survey, British Journal of Clinical Pharmacology, vol.47, issue.2, pp.320-322, 2008.
DOI : 10.1111/j.1365-2125.2008.03193.x

R. Lafyatis, . Kissin, . York, . Farina, M. Viger et al., B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis, Arthritis & Rheumatism, vol.56, issue.2, pp.578-583, 2009.
DOI : 10.1002/art.24249

C. Melander, . Sallée, . Trolliet, . Candon, E. Belenfant et al., Rituximab in Severe Lupus Nephritis: Early B-Cell Depletion Affects Long-Term Renal Outcome, Clinical Journal of the American Society of Nephrology, vol.4, issue.3, pp.579-587, 2009.
DOI : 10.2215/CJN.04030808

A. Ø. Jensen, B. K. Møller, A. Vangkilde, B. Mark, E. R. Obitz et al., Treatment of treatment-resistant autoimmune blistering skin disorders with rituximab, British Journal of Dermatology, vol.128, issue.6, pp.1335-1362, 2009.
DOI : 10.1111/j.1365-2133.2009.09132.x

M. Martinez-del-pero, A. Chaudhry, R. B. Jones, P. Sivasothy, P. Jani et al., B-cell depletion with rituximab for refractory head and neck Wegener???s granulomatosis: a cohort study, Clinical Otolaryngology, vol.22, issue.4
DOI : 10.1111/j.1749-4486.2009.01968.x

J. Meijer, . Meiners, . Vissink, . Spijkervet, N. Abdulahad et al., Effective rituximab treatment in primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled trial, 2010.

F. Catapano, A. N. Chaudhry, R. B. Jones, K. G. Smith, and D. W. Jayne, Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus, Nephrology Dialysis Transplantation, vol.25, issue.11, pp.1-7, 2010.
DOI : 10.1093/ndt/gfq256

E. P. Rhee, K. A. Laliberte, and J. L. Niles, Rituximab as Maintenance Therapy for

B. Terrier, Z. Amoura, E. Ravaud, R. Hachulla, and B. Jouenne, Combe et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AIR registry